Kanghong Pharmaceutical released its 2026 interim report. Total operating revenue was 2.179 billion yuan, down 11.19% from the same period last year. Net profit attributable to the parent company was 565 million yuan, down 22.61% year on year. Net cash inflow from operating activities was 540 million yuan, down 41.06% year on year. The company's latest asset-liability ratio was 7.63%, gross margin was 88.50%, ROE was 6.13%, and diluted earnings per share was 0.61 yuan, down 22.78% year on year. The number of shareholders was 37,900, and the top ten shareholders held 72.84% of the total share capital.
Chengdu Kanghong Pharmaceuticals Group Co LtdNet profit fell 22.61% year on year, revenue down 11.19%, and operating cash flow down 41.06%.
